Does efficacy decline over time (tachyphylaxis)
Heart rate elevation persists during use but appears to normalize after discontinuation based on data from similar drugs
Collectively, these features may have reduced the precision of cross-arm estimates and increased the probability of type II error
Other exclusion criteria were treatment with an SGLT-2I, GLP-1RA or dipeptidyl-peptidase 4 inhibitor (DPP4-I) within 30 days before randomisation, a cardio- or cerebrovascular event within the last 90 days or planned revascularisation
353b), the FAQs state that compounding drugs, including GLP-1s, is appropriate either when the drug is not commercially available (including if there is an FDA-declared shortage) or when the compounded drug includes a change, made for an identified individual patient, which produces for that patient a significant difference, as determined by the prescribing practitioner, between the compounded drug and the commercially available product. In short, compounding pharmacies will no longer be able to produce copies of commercially available drugs, including GLP-1s
As access expands, so must medical responsibility for doctors, platforms, and patients alike
